Autor: |
Wu K; Department of Immunology, School of Medicine, Keimyung University, Daegu 42601, Korea., Woo SM; Department of Immunology, School of Medicine, Keimyung University, Daegu 42601, Korea., Seo SU; Department of Immunology, School of Medicine, Keimyung University, Daegu 42601, Korea., Kwon TK; Department of Immunology, School of Medicine, Keimyung University, Daegu 42601, Korea.; Center for Forensic Pharmaceutical Science, Keimyung University, Daegu 42601, Korea. |
Abstrakt: |
BMI-1, a polycomb ring finger oncogene, is highly expressed in multiple cancer cells and is involved in cancer cell proliferation, invasion, and apoptosis. BMI-1 represents a cancer stemness marker that is associated with the regulation of stem cell self-renewal. In this study, pharmacological inhibition (PTC596) or knockdown (siRNA) of BMI-1 reduced cancer stem-like cells and enhanced cancer cell death. Mechanistically, the inhibition of BMI-1 induced the downregulation of Mcl-1 protein, but not Mcl-1 mRNA. PTC596 downregulated Mcl-1 protein expression at the post-translational level through the proteasome-ubiquitin system. PTC596 and BMI-1 siRNA induced downregulation of DUB3 deubiquitinase, which was strongly linked to Mcl-1 destabilization. Furthermore, overexpression of Mcl-1 or DUB3 inhibited apoptosis by PTC596. Taken together, our findings reveal that the inhibition of BMI-1 induces Mcl-1 destabilization through downregulation of DUB3, resulting in the induction of cancer cell death. |